



08-22-07

IFW

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/617,489
		Filing Date	July 10, 2003
		First Named Inventor	Thomas L. CANTOR
		Art Unit	1641
		Examiner Name	C. Cheu
Total Number of Pages in This Submission	11	Attorney Docket Number	532212000623

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	PTO/SB/08a/b (4 pages plus duplicate)
<input checked="" type="checkbox"/> Information Disclosure Statement (2 pages)	<input type="checkbox"/> CD, Number of CD(s) _____	References (93)
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	Return Receipt Postcard
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	Remarks CUSTOMER NO.: 25225	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT


Firm Name	MORRISON & FOERSTER LLP		
Signature			
Printed name	Peng Chen		
Date	August 20, 2007	Reg. No.	43,543

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EM 057522035 US, on the date shown below in an envelope addressed to: MS Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: August 20, 2007

Signature:

(Lenay Rogus)



I hereby certify that this paper (along with any paper referred to as being attached and enclosed) is being deposited with the U.S. Postal Service as Express Mail, Air Mail No. 957522035 US, on the date shown below in an envelope addressed to: MS Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: August 20, 2007

Signature:

[Signature]
(Lenay Rogus)

Patent

Docket No. 532212000623

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Thomas L. CANTOR

Serial No.: 10/617,489

Filing Date: July 10, 2003

For: METHODS, KITS AND ANTIBODIES
FOR DETECTING PARATHYROID
HORMONE

Examiner: C. Cheu

Group Art Unit: 1641

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

MS Issue Fee
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

The documents set forth on the enclosed Form PTO/SB/08a/b have not been submitted or cited in the present application. It is understood that the Office is under no obligation to consider these documents at this time; however, to complete the record they are submitted. Copies of the non-patent literature documents are enclosed.

Document numbers 33 and 125 are from the prosecution of Applicants' related application number 10/945,608. Document numbers 34-36 are from the prosecution of Applicants' application number 10/799,476. Document numbers 66 and 67 were cited in application number 10/799,476. Document numbers 37-50 are from the prosecution of Applicants' application number 10/265,276. Document numbers 68-77 were cited in application number 10/265,276. Document

sd-388275

numbers 51-61 are from the prosecution of Applicants' application number 10/674,294. Document numbers 62-64 are from the prosecution of Applicants' application number 10/958,541. Document numbers 78-94 were cited in application number 10/958,541. Document number 65 is from the prosecution of Applicants' application number 11/516,912. Document numbers 95-124 were cited in application number 11/516,912.


Applicants believe that the documents are in no way destructive of patentability of the allowed claims. However, in the interest of completeness, they are submitted herewith.


The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 532212000623.

Dated: August 20, 2007

Respectfully submitted,

By 
Peng Chen
Registration No.: 43,543
MORRISON & FOERSTER LLP
12531 High Bluff Drive, Suite 100
San Diego, California 92130-2040
(858) 720-5117



ALTERNATIVE TO PTO/SB/08A/B (04/07)

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/617,489
				Filing Date	July 10, 2003
				First Named Inventor	Thomas L. CANTOR
				Art Unit	1641
				Examiner Name	C. Cheu
Sheet	1	of	4	Attorney Docket Number	532212000623

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1.	US-4,086,196	04/1978	Tregear	
	2.	US-4,851,356	07/1989	Canfield et al.	
	3.	US-4,968,669	11/1990	Rosenblatt et al.	
	4.	US-5,026,653	06/1991	Lee et al.	
	5.	US-5,075,218	12/1991	Jette et al.	
	6.	US-5,093,233	03/1992	Rosenblatt et al.	
	7.	US-5,208,041	05/1993	Sindrey	
	8.	US-5,256,543	10/1993	Pouletty et al.	
	9.	US-5,317,010	05/1994	Pang et al.	
	10.	US-5,382,658	01/1995	Kronis et al.	
	11.	US-5,434,246	07/1995	Fukuda et al.	
	12.	US-5,496,801	03/1996	Holthuis et al.	
	13.	US-5,589,452	12/1996	Krstenansky et al.	
	14.	US-5,639,617	06/1997	Bohuon	
	15.	US-5,695,955	12/1997	Krstenansky et al.	
	16.	US-5,723,577	03/1998	Dong	
	17.	US-5,747,456	05/1998	Chorev et al.	
	18.	US-5,783,558	07/1998	Duvos et al.	
	19.	US-5,798,225	08/1998	Krstenansky et al.	
	20.	US-5,807,823	09/1998	Krstenansky et al.	
	21.	US-5,840,831	11/1998	Hamachi et al.	
	22.	US-5,955,264	09/1999	Seed et al.	
	23.	US-5,958,384	09/1999	Holick et al.	
	24.	US-6,124,314	09/2000	Cameron et al.	
	25.	US-6,387,711	05/2002	Sundaram et al.	
	26.	US-6,689,566	02/2004	Cantor et al.	
	27.	US-2003/0171288	09/2003	Andrew et al.	
	28.	US-2004/0067526	04/2004	Cantor	
	29.	US-2005/0069952	03/2005	Cantor et al.	
	30.	US-2005/0170443	08/2005	Cantor	
	31.	US-2005/0202506	09/2005	Cantor	
	32.	US-2007/0098726	05/2007	Cantor et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

sd- 388281

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/617,489
				Filing Date	July 10, 2003
				First Named Inventor	Thomas L. CANTOR
				Art Unit	1641
				Examiner Name	C. Cheu
Sheet	2	of	4	Attorney Docket Number	532212000623

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	33.	Advisory Action from 10/945,608, mailed on July 23, 2007		
	34.	Restriction Requirement from 10/799,476, mailed on January 10, 2007		
	35.	Response to Restriction Requirement from 10/799,476, filed on January 24, 2007		
	36.	Non-Final Office Action from 10/799,476, mailed on April 17, 2007		
	37.	Restriction Requirement from 10/265,276, mailed on August 20, 2004		
	38.	Response to Restriction Requirement from 10/265,276, filed on December 18, 2004		
	39.	Non-Final Office Action from 10/265,276, mailed on January 24, 2005		
	40.	Amendment in Response to Non-Final Office Action from 10/265,276, filed on April 25, 2005		
	41.	Non-Final Office Action from 10/265,276, mailed on June 28, 2005		
	42.	Amendment in Response to Non-Final Office Action from 10/265,276, filed on October 7, 2005		
	43.	Final Rejection from 10/265,276, mailed on January 4, 2006		
	44.	Amendment After Final Action (37 CFR Section 1.116) from 10/265,276, filed on April 4, 2006		
	45.	Advisory Action from 10/265,276, mailed on May 18, 2006		
	46.	Pre-Appeal Brief Request for Review from 10/265,276, filed on June 13, 2006		
	47.	Notice of Panel Decision from Pre-Appeal Brief Review from 10/265,276, mailed on August 4, 2006		
	48.	Non-Final Office Action from 10/265,276, mailed on October 20, 2006		
	49.	Amendment in Response to Non-Final Office Action from 10/265,276, filed on January 19, 2007		
	50.	Final Rejection from 10/265,276, mailed on April 19, 2007		
	51.	Restriction Requirement from 10/674,294, mailed on June 2, 2006		
	52.	Response to Restriction Requirement from 10/674,294, filed on June 28, 2006		
	53.	Non-Final Office Action from 10/674,294, mailed on September 11, 2006		
	54.	Amendment in Response to Non-Final Office Action from 10/674,294, filed on December 13, 2006		
	55.	Final Rejection from 10/674,294, mailed on February 15, 2007		
	56.	Amendment After Final Action Under 37 CFR 1.116 from 10/674,294, filed on April 13, 2007		
	57.	Advisory Action from 10/674,294, mailed on April 27, 2007		
	58.	Examiner Interview Summary from 10/674,294, mailed on May 17, 2007		
	59.	Amendment After Final Action Under 37 CFR 1.116 from 10/674,294, filed on May 18, 2007		
	60.	Substance of Examiner Interview from 10/674,294, filed on June 14, 2007		
	61.	Non-Final Office Action from 10/674,294, mailed on June 18, 2007		
	62.	Restriction Requirement from 10/958,541, mailed on March 7, 2007		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/617,489
				Filing Date	July 10, 2003
				First Named Inventor	Thomas L. CANTOR
				Art Unit	1641
				Examiner Name	C. Cheu
Sheet	3	of	4	Attorney Docket Number	532212000623

63.	Response to Restriction Requirement from 10/958,541, filed on April 4, 2007	
64.	Non-Final Office Action from 10/958,541, mailed on August 3, 2007	
65.	Restriction Requirement from 11/516,912, mailed on July 31, 2007	
66.	CANFIELD et al., Endocrinology (1982) 110(5):1555-1563	
67.	MOTTE et al., Journal of Immunology (1987) 138(10):3332-3338	
68.	KURIYAMA et al., Blood Purification (1998) 16:43-48	
69.	MONIER-FAUGERE et al., Journal of the American Society of Nephrology (1999) 11:1093-1099	
70.	NISSONSEN et al., J. Biol. Chem. (1988) 263(26):12866-12871	
71.	PARTHEMORE et al., J. Clin. Endocrinol. Metab. (1978) 47(2):284-289	
72.	PODBESEK et al., Endocrinology (1983) 112:1000-1006	
73.	RICHARDS et al., Clin. Nephrol. (1999) 51(2):126-127	
74.	STAFFORD-JOHNSON et al., J. Comput. Assist. Tomogr. (1998) 22(2):295-299	
75.	STEWART et al., J. Clin. Invest. (1988) 81(2):596-600	
76.	THOMPSON et al., PNAS USA (1988) 85(15):5673-5677	
77.	YATES et al., J. Clin. Invest. (1988) 81(3):932-938	
78.	BHASKARAN and PONNUSWAMY, Int. J. Pept. Protein Res. (1988) 32:242-255	
79.	D'AMOUR et al., Endocrinology (1985) 117:127-134	
80.	D'AMOUR et al., J. Immunoassay (1989) 10:191-205	
81.	DELEAGE and ROUX, Protein Engineering (1987) 1:289-294	
82.	GHILLANI et al., Cancer Res. (1989) 49(23):6845-6851	
83.	HENIKOFF et al., PNAS USA (1992) 89:10915-10919	
84.	HOPP and WOODS, PNAS USA (1981) 78:3824-3828	
85.	JANIN, Nature (1979) 277:491-492	
86.	KYTE and DOOLITTLE, J. Mol. Biol. (1982) 157:105-132	
87.	LEI et al., J. Biol. Chem. (1995) 270(20):1182-1186	
88.	LOVERIDGE et al., Endocrinology (1991) 128(4):1938-1946	
89.	MERRIFIELD et al., Biochemistry (1982) 21:5020	
90.	NIALL et al., PNAS USA (1969) 64:771-778	
91.	RABBANI et al., J. Biol. Chem. (1984) 259:2949-2955	
92.	STEVENS et al., Journal of Immunological Methods (1988) 108:271-278	
93.	STRYER, (ed.), Biochemistry 2 nd ed., (1981) pp. 13-16	
94.	JANEWAY et al., Immunobiology, 5 th ed., Appendix I, pages 624-625	
95.	BERSON et al., J. Clin. Invest. (1956) 35:170-190	
96.	BERSON et al., PNAS USA (1963) 49:613-617	
97.	BROADUS et al., J. Clin. Invest. (1977) 60:771-783	
98.	BROSSARD et al., J. Bone and Miner. Res. (1999) 14:S444	
99.	CANTERBURY et al., J. Clin. Invest. (1975) 55:1245-1253	
100.	DAMBACHER et al., Clinical Science (1979) 57:435-443	
101.	ENDRES et al., Kidney International (1982) 21:132	
102.	FLUECK et al., Proceedings of the 58th American Meeting of the Endocrine Society, June 1976	
103.	FREITAG et al., New England Journal of Medicine (1978) 298:29-32	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/617,489
				Filing Date	July 10, 2003
				First Named Inventor	Thomas L. CANTOR
				Art Unit	1641
				Examiner Name	C. Cheu
Sheet	4	of	4	Attorney Docket Number	532212000623

	104.	GALLAGHER et al., J. Lab. Clin. Med. (1980) 95:373-385	
	105.	HABENER and POTTS, New England Journal of Medicine (1978) 299:580-585, 635-644	
	106.	KAO et al., Clin. Chem. (1982) 28:69-74	
	107.	KEUTMANN et al., Biochemistry (1978) 17:5723-5729	
	108.	LAFFERTY, Medicine (1966) 45:247-260	
	109.	MALLETTE et al., J. Clin. Endocrinology Metab. (1982) 54:1017-1024	
	110.	MALLETTE, Ligand Review (1979) 1:18-19	
	111.	NUSSBAUM et al., Clin. Chem. (1988) 33(8):1364-1367	
	112.	RAISZ et al., Annals International Medicine (1979) 91:739-740	
	113.	RODBARD and HUTT, "Statistical Analysis of Radioimmunoassays and Immunoradiometric (labeled antibody) Assays" in Assays, Radioimmunoassays and Related Procedures in Medicine, Vol. 1, Vienna: International Atomic Energy Agency, Vienna, (1974) pp. 165-192	
	114.	RODBARD et al., J. Clin. Endocrinology Metab. (1968) 28:1412-1418	
	115.	ROOS et al., J. Clin. Endocrinology and Metab. (1981) 53:709-721	
	116.	SEGRE et al., American Journal of Medicine (1974) 56:774-784	
	117.	SEGRE et al., Biochemistry (1977) 16:2417-2427	
	118.	SEGRE et al., J. Clin. Invest. (1981) 67:439-448	
	119.	SEGRE et al., J. Clin. Invest. (1981) 67:449-457	
	120.	SEGRE et al., J. Clin. Invest. (1972) 51:3163-3172	
	121.	SILVERMAN and YALOW, J. Clin. Invest. (1973) 52:1958-1971	
	122.	SLATOPOLSKY et al., Journal of American Society of Nephrology (1999) 10:625A	
	123.	TRAVIS, (ed.), "Clinical Radioimmunoassay" in State-of-the-Art Scientific Newsletter, Inc., Anaheim, CA 92803, (1980) pp.13-16	
	124.	WOOD et al., J. Clin. Chem. Biochemistry (1980) 18:789-795	
	125.	Request for Continued Examination from 10/945,608, filed on August 2, 2007	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

sd-388281